CTNNB1 and melanoma: Given the low frequency of somatic APC/CTNNB1 mutations in melanoma (approximately 10–12% across all stages), the comparator arms were largely unbalanced, which may be the reason why APC/CTNNB1 somatic mutations were associated with worse prognosis in stage IV, and only trended towards significance in stage III melanoma.